Virax Biolabs Jumps on Fosun Diagnostics Supply Agreement

Virax Biolabs Group Limited (VRAX) is up 234.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp move appears to be driven primarily by Virax’s July 9 announcement of an exclusive multi-country commercial supply agreement with Fosun Diagnostics. Investors likely viewed the deal as meaningful because it creates a framework for immediate product supply, opens six Southeast Asian markets, and points to near-term revenue potential for the company’s ImmuneSelect product line. The magnitude of the rally may also have been amplified by the stock’s recent 1-for-25 share consolidation, which can increase volatility in small-cap names.

Details:

Virax said its UK subsidiary signed an exclusive commercial supply agreement with Fosun Diagnostics covering Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia.

The agreement applies to ImmuneSelect, Virax’s research-use immune profiling product line, and management described it as a near-term commercial opportunity separate from the company’s in-development ViraxImmune platform.

Virax said the arrangement supports immediate supply through purchase orders, with room for expanded product offerings, higher-volume arrangements, and possible OEM or private-label work.

Less than two weeks before the surge, Virax completed a 1-for-25 share consolidation to regain compliance with Nasdaq’s minimum bid price requirement, a setup that can sometimes intensify price swings after fresh news.

Sources:

Virax Biolabs Investor Relations, Nasdaq Trader, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive VRAX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$VRAX Hedge Fund Activity

We have seen 2 institutional investors add shares of $VRAX stock to their portfolio, and 3 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ARMISTICE CAPITAL, LLC added 878,803 shares (+inf%) to their portfolio in Q1 2026, for an estimated $193,248
JUMP FINANCIAL, LLC added 40,724 shares (+inf%) to their portfolio in Q1 2026, for an estimated $8,955
XTX TOPCO LTD removed 21,437 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $4,713
UBS GROUP AG removed 7,492 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,647
NATIONAL BANK OF CANADA /FI/ removed 6,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,319
FARTHER FINANCE ADVISORS, LLC added 0 shares (+0.0%) to their portfolio in Q1 2026, for an estimated $0
OSAIC HOLDINGS, INC. added 0 shares (+0.0%) to their portfolio in Q1 2026, for an estimated $0

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.